Niquette Hunt

Niquette Hunt has extensive experience in the healthcare and biotechnology industries. Niquette is the President, CEO, and Board Chair of Candesant Biomedical, a company they founded in 2016 with a focus on developing a treatment for excessive sweating and hyperhidrosis. Niquette's leadership has led to the development of CDX-101, a non-invasive, topical patch for excessive sweating.

In addition to their role at Candesant Biomedical, Niquette serves as a Board Member for Minerva Surgical, Inc. since 2021 and was a Board Member for Soliton, Inc. from 2020 to 2021.

Before their current roles, Niquette worked as a Principal at McLean Hunt Consulting Group from 2001 to 2018. Niquette specialized in marketing and commercial development strategies for medical device and biotechnology companies. Niquette has also held notable positions, such as the SVP of Commercial Development at Revance Therapeutics, where they took the company public and raised significant funds.

Throughout their career, Niquette has demonstrated accomplished results, including reducing costs and improving sales conversion rates as Interim VP of Marketing at Amira Medical. Niquette also increased product revenues by 37% as VP of Marketing at ChemTrak. Prior to that, they served as a Director at Warner Lambert, overseeing various franchises with P&L responsibility. Niquette began their career as a Brand Manager at Procter and Gamble, where they successfully executed marketing plans leading to market share growth.

Niquette Hunt's diverse background in leadership, marketing, and commercialization within the healthcare industry has positioned their as a highly experienced professional capable of driving innovative solutions and successful business strategies.

Niquette Hunt's education history includes studying at Stanford University, where they pursued a degree in Engineering and Economics. However, the specific start and end years of their education at Stanford University are not mentioned.